Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| Today 4:17 PM View:  | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | Yesterday | Planned Option Sale | 100 | $15.00 | $1,500.00 | (< 1%) 67.1K to 67.0K | |
| Today 4:17 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | Yesterday | Option Exercise | 100 | $1.08 | $108.00 | < 1% 67.0K to 67.1K | |
| 15-Apr-24 4:24 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 12-Apr-24 | Option Exercise | 6,349 | $1.08 | $6,856.92 | 10% 60.65K to 67.0K | |
| 15-Apr-24 4:24 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Apr-24 | Option Exercise | 5,017 | $0.54 | $2,709.18 | 9% 55.63K to 60.65K | |
| 13-Mar-24 5:35 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 12-Mar-24 | Option Exercise | 6,348 | $1.08 | $6,855.84 | 13% 49.28K to 55.63K | |
| 13-Mar-24 5:35 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Mar-24 | Option Exercise | 5,017 | $0.54 | $2,709.18 | 11% 44.27K to 49.28K | |
| 13-Feb-24 4:08 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 12-Feb-24 | Option Exercise | 11,366 | $0.84 | $9,566.10 | 35% 32.9K to 44.27K | |
| 14-Feb-24 7:49 PM View: | Ra Capital Management, LLC Director | Mineralys Therapeutics, Inc. (MLYS) | 12-Feb-24 | Grant | 1,672,510 | $13.50 | $22,578,900.00 | 53% 3.18M to 4.85M | 5% |
| 14-Feb-24 9:06 PM View: | Samsara Biocapital Gp, LLC 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 12-Feb-24 | Market Purchase | 555,555 | $13.50 | $7,499,990.00 | 12% 4.52M to 5.07M | 5% |
| 14-Feb-24 9:07 PM View: | Akkaraju Srinivas Director 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 12-Feb-24 | Grant | 555,555 | $13.50 | $7,499,990.00 | 12% 4.52M to 5.07M | 5% |
| 12-Jan-24 4:01 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 12-Jan-24 | Option Exercise | 6,348 | $1.08 | $6,855.84 | 24% 26.55K to 32.9K | |
| 12-Jan-24 4:01 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Jan-24 | Option Exercise | 5,017 | $0.54 | $2,709.18 | 23% 21.54K to 26.55K | |
| 12-Dec-23 5:08 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Dec-23 | Option Exercise | 5,018 | $0.54 | $2,709.72 | 33% 15.05K to 20.07K | |
| 27-Nov-23 4:01 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 22-Nov-23 | Private Purchase | 4,250 | $5.97 | $25,355.90 | < 1% 1.04M to 1.05M | |
| 14-Nov-23 6:18 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 13-Nov-23 | Option Exercise | 5,017 | $0.54 | $2,709.18 | 50% 10.03K to 15.05K | |
| 07-Nov-23 5:15 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 03-Nov-23 | Option Exercise | 10,034 | $0.54 | $5,418.36 | 100% 0 to 10.03K | |
| 08-Sep-23 8:49 AM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 06-Sep-23 | Private Purchase | 2,250 | $12.08 | $27,180.00 | < 1% 1.04M to 1.04M | |
| 21-Aug-23 4:03 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 17-Aug-23 | Private Purchase | 2,250 | $12.10 | $27,225.00 | < 1% 1.04M to 1.04M | |
| 11-Aug-23 7:11 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Aug-23 | Option Sale | 157,091 | $12.81 | $2,012,340.00 | (100%) 157.09K to 0 | |
| 11-Aug-23 7:11 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 11-Aug-23 | Option Exercise | 157,091 | $0.80 | $125,967.00 | 100% 0 to 157.09K | |
| 11-Aug-23 7:11 PM View: | Congleton Jon Chief Executive Officer Director | Mineralys Therapeutics, Inc. (MLYS) | 11-Aug-23 | Market Purchase | 2,000 | $12.89 | $25,780.00 | < 1% 1.04M to 1.04M | 10% |
| 11-Aug-23 7:11 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 10-Aug-23 | Option Exercise | 74,625 | $0.54 | $40,297.50 | 100% 0 to 74.63K | |
| 11-Aug-23 7:11 PM View: | Rodman David Malcom Chief Medical Officer | Mineralys Therapeutics, Inc. (MLYS) | 10-Aug-23 | Option Sale | 74,625 | $13.16 | $982,065.00 | (100%) 74.63K to 0 | |
| 16-Feb-23 5:04 PM View: | Ra Capital Management, LLC Director | Mineralys Therapeutics, Inc. (MLYS) | 14-Feb-23 | Conversion | 1,928,480 | -- | -- | 100% 0 to 1.93M | |
| 16-Feb-23 9:00 PM View: | Hbm Bioventures Cayman Ltd 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 14-Feb-23 | Conversion | 2,905,610 | -- | -- | 100% 0 to 2.91M | |
| 16-Feb-23 4:54 PM View: | Akkaraju Srinivas Director 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 14-Feb-23 | Conversion | 3,581,860 | -- | -- | 100% 0 to 3.58M | |
| 16-Feb-23 4:54 PM View: | Slingsby Brian Taylor Director 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 14-Feb-23 | Conversion | 4,314,090 | -- | -- | 93% 4.63M to 8.94M | |
| 16-Feb-23 5:04 PM View: | Ra Capital Management, LLC Director | Mineralys Therapeutics, Inc. (MLYS) | 14-Feb-23 | Private Purchase | 1,250,000 | $16.00 | $20,000,000.00 | 65% 1.93M to 3.18M | |
| 16-Feb-23 9:00 PM View: | Hbm Bioventures Cayman Ltd 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 14-Feb-23 | Private Purchase | 312,500 | $16.00 | $5,000,000.00 | 11% 2.91M to 3.22M | |
| 16-Feb-23 4:54 PM View: | Levy Adam Scott CFO, Chief Bus. Off. and Secy. | Mineralys Therapeutics, Inc. (MLYS) | 14-Feb-23 | Private Purchase | 6,250 | $16.00 | $100,000.00 | 2% 344.56K to 350.81K | |
| 16-Feb-23 4:54 PM View: | Akkaraju Srinivas Director 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 14-Feb-23 | Private Purchase | 937,500 | $16.00 | $15,000,000.00 | 26% 3.58M to 4.52M | |
| 16-Feb-23 4:54 PM View: | Slingsby Brian Taylor Director 10% Owner | Mineralys Therapeutics, Inc. (MLYS) | 14-Feb-23 | Private Purchase | 250,000 | $16.00 | $4,000,000.00 | 3% 8.94M to 9.19M |
